VIVENDI : UBS confirms its buy recommendation
UBS confirms its buy recommendation on the stock and its price target of E15.2, which represents a potential upside of 48%.
' Vivendi reported organic growth of +2.6% for FY 2023, with EBITA slightly ahead of expectations. Havas posted organic growth of +4.7% in Q4 2023. No new information on the proposed demerger' says the research firm.
The group reported net income, group share of 405 million euros in 2023 (0.40 euro per basic share), compared with a loss of 1,010 million euros in 2022 (-0.98 euro per basic share), an increase of 1,415 million euros.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction